Raquelle Mesholam-Gately, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 61 | 2023 | 6882 | 2.710 |
Why?
|
| Schizophrenic Psychology | 20 | 2022 | 1678 | 1.500 |
Why?
|
| Psychotic Disorders | 20 | 2024 | 3046 | 1.140 |
Why?
|
| Cognition Disorders | 17 | 2022 | 4043 | 0.770 |
Why?
|
| Verbal Learning | 4 | 2014 | 468 | 0.750 |
Why?
|
| Neuropsychological Tests | 27 | 2022 | 6994 | 0.670 |
Why?
|
| Diffusion Tensor Imaging | 16 | 2022 | 2305 | 0.530 |
Why?
|
| Event-Related Potentials, P300 | 5 | 2020 | 150 | 0.530 |
Why?
|
| Evoked Potentials, Auditory | 4 | 2019 | 525 | 0.470 |
Why?
|
| Cognition | 17 | 2023 | 6770 | 0.420 |
Why?
|
| Corpus Callosum | 5 | 2019 | 737 | 0.420 |
Why?
|
| Smell | 1 | 2014 | 244 | 0.410 |
Why?
|
| Clozapine | 1 | 2014 | 498 | 0.370 |
Why?
|
| Evoked Potentials, Visual | 3 | 2020 | 427 | 0.350 |
Why?
|
| Intelligence | 2 | 2017 | 920 | 0.340 |
Why?
|
| Memory Disorders | 2 | 2013 | 1186 | 0.310 |
Why?
|
| Social Perception | 4 | 2019 | 425 | 0.300 |
Why?
|
| Reward | 1 | 2014 | 940 | 0.300 |
Why?
|
| Lateral Ventricles | 2 | 2019 | 147 | 0.290 |
Why?
|
| Psychiatric Status Rating Scales | 14 | 2019 | 6036 | 0.270 |
Why?
|
| Memory | 3 | 2015 | 2174 | 0.240 |
Why?
|
| Brain | 17 | 2022 | 26388 | 0.240 |
Why?
|
| Anisotropy | 8 | 2022 | 1265 | 0.230 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 3057 | 0.200 |
Why?
|
| Endophenotypes | 3 | 2017 | 250 | 0.190 |
Why?
|
| Young Adult | 34 | 2020 | 56429 | 0.180 |
Why?
|
| Memory, Short-Term | 5 | 2022 | 977 | 0.180 |
Why?
|
| Emotional Intelligence | 1 | 2019 | 136 | 0.150 |
Why?
|
| Myelin Sheath | 2 | 2019 | 652 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 11 | 2019 | 8949 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 4257 | 0.150 |
Why?
|
| Attention | 4 | 2019 | 2397 | 0.150 |
Why?
|
| Aptitude | 1 | 2017 | 45 | 0.150 |
Why?
|
| Frontal Lobe | 2 | 2015 | 1406 | 0.150 |
Why?
|
| Factor Analysis, Statistical | 5 | 2019 | 977 | 0.150 |
Why?
|
| Analysis of Variance | 7 | 2016 | 6366 | 0.140 |
Why?
|
| Limbic System | 1 | 2019 | 426 | 0.140 |
Why?
|
| Psychometrics | 8 | 2019 | 3003 | 0.140 |
Why?
|
| Humans | 71 | 2024 | 744366 | 0.140 |
Why?
|
| Attitude | 1 | 2021 | 776 | 0.140 |
Why?
|
| Cannabis | 1 | 2023 | 440 | 0.140 |
Why?
|
| Electroencephalography | 6 | 2020 | 6151 | 0.140 |
Why?
|
| Auditory Cortex | 1 | 2019 | 346 | 0.140 |
Why?
|
| Adult | 40 | 2022 | 214052 | 0.130 |
Why?
|
| Parahippocampal Gyrus | 1 | 2016 | 116 | 0.130 |
Why?
|
| Delusions | 2 | 2015 | 300 | 0.130 |
Why?
|
| Social Stigma | 1 | 2021 | 701 | 0.130 |
Why?
|
| Male | 49 | 2021 | 350115 | 0.130 |
Why?
|
| Gyrus Cinguli | 3 | 2019 | 1091 | 0.130 |
Why?
|
| Fluphenazine | 1 | 2014 | 36 | 0.120 |
Why?
|
| Caudate Nucleus | 1 | 2016 | 393 | 0.120 |
Why?
|
| Fornix, Brain | 1 | 2014 | 70 | 0.120 |
Why?
|
| Female | 49 | 2021 | 380193 | 0.120 |
Why?
|
| Brain Mapping | 8 | 2022 | 6670 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2016 | 651 | 0.110 |
Why?
|
| Adolescent | 24 | 2022 | 85779 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2022 | 35425 | 0.110 |
Why?
|
| Risk | 7 | 2020 | 9688 | 0.110 |
Why?
|
| Thalamus | 1 | 2019 | 1023 | 0.110 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2014 | 957 | 0.110 |
Why?
|
| Prefrontal Cortex | 3 | 2020 | 2147 | 0.110 |
Why?
|
| Family | 2 | 2021 | 3147 | 0.110 |
Why?
|
| Haloperidol | 1 | 2014 | 397 | 0.110 |
Why?
|
| Depression | 1 | 2011 | 7759 | 0.100 |
Why?
|
| Interview, Psychological | 2 | 2014 | 812 | 0.100 |
Why?
|
| Language Disorders | 1 | 2012 | 141 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 504 | 0.100 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 12262 | 0.090 |
Why?
|
| GABA Agonists | 1 | 2010 | 111 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2016 | 2634 | 0.090 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 238 | 0.090 |
Why?
|
| Disease Progression | 4 | 2016 | 13286 | 0.090 |
Why?
|
| Pyridazines | 1 | 2010 | 202 | 0.080 |
Why?
|
| Executive Function | 1 | 2017 | 1364 | 0.080 |
Why?
|
| Organ Size | 3 | 2018 | 2251 | 0.080 |
Why?
|
| Nerve Degeneration | 1 | 2012 | 748 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1941 | 0.080 |
Why?
|
| Parietal Lobe | 1 | 2013 | 838 | 0.080 |
Why?
|
| Social Behavior | 4 | 2019 | 1127 | 0.080 |
Why?
|
| Neural Pathways | 4 | 2019 | 2974 | 0.070 |
Why?
|
| Family Health | 1 | 2012 | 1281 | 0.070 |
Why?
|
| Genetic Loci | 1 | 2016 | 2575 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2018 | 2737 | 0.070 |
Why?
|
| Hippocampus | 2 | 2023 | 3675 | 0.070 |
Why?
|
| Corpus Striatum | 1 | 2013 | 1221 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1410 | 0.070 |
Why?
|
| Cerebral Cortex | 2 | 2022 | 5709 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 1901 | 0.070 |
Why?
|
| Bipolar Disorder | 1 | 2023 | 5027 | 0.070 |
Why?
|
| Outpatients | 3 | 2019 | 1487 | 0.060 |
Why?
|
| Triazoles | 1 | 2010 | 908 | 0.060 |
Why?
|
| Middle Aged | 16 | 2019 | 213390 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 17446 | 0.060 |
Why?
|
| National Institute of Mental Health (U.S.) | 3 | 2008 | 107 | 0.060 |
Why?
|
| Reference Values | 4 | 2016 | 4982 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2010 | 2539 | 0.060 |
Why?
|
| Social Adjustment | 2 | 2019 | 631 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2022 | 15520 | 0.050 |
Why?
|
| Early Diagnosis | 2 | 2019 | 1184 | 0.050 |
Why?
|
| Acute Disease | 3 | 2018 | 7147 | 0.050 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 13991 | 0.050 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 7914 | 0.050 |
Why?
|
| Case-Control Studies | 5 | 2016 | 21748 | 0.040 |
Why?
|
| Mental Recall | 2 | 2014 | 1206 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2016 | 2373 | 0.040 |
Why?
|
| Age of Onset | 2 | 2015 | 3270 | 0.040 |
Why?
|
| Emotions | 2 | 2020 | 2659 | 0.040 |
Why?
|
| Theory of Mind | 1 | 2019 | 86 | 0.040 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 25039 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2018 | 6459 | 0.030 |
Why?
|
| Functional Laterality | 2 | 2013 | 2290 | 0.030 |
Why?
|
| Demography | 1 | 2021 | 1655 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2019 | 1216 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 1681 | 0.030 |
Why?
|
| Expert Testimony | 2 | 2008 | 356 | 0.030 |
Why?
|
| Child | 5 | 2023 | 77709 | 0.030 |
Why?
|
| Time Factors | 3 | 2014 | 40075 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 57776 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 1195 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 39052 | 0.030 |
Why?
|
| Water | 1 | 2020 | 1395 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 19905 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2022 | 63107 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2018 | 1655 | 0.030 |
Why?
|
| Advisory Committees | 2 | 2008 | 775 | 0.030 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2013 | 108 | 0.030 |
Why?
|
| Hallucinations | 1 | 2015 | 360 | 0.030 |
Why?
|
| Genotype | 2 | 2017 | 12952 | 0.030 |
Why?
|
| Drug Design | 2 | 2008 | 1076 | 0.030 |
Why?
|
| Psychotropic Drugs | 2 | 2008 | 894 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 2887 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2019 | 1534 | 0.020 |
Why?
|
| Aged | 5 | 2017 | 163288 | 0.020 |
Why?
|
| Massachusetts | 1 | 2024 | 8662 | 0.020 |
Why?
|
| Alleles | 1 | 2022 | 6933 | 0.020 |
Why?
|
| California | 1 | 2014 | 1402 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 280 | 0.020 |
Why?
|
| Speech Perception | 1 | 2014 | 490 | 0.020 |
Why?
|
| Software | 2 | 2016 | 4441 | 0.020 |
Why?
|
| Learning | 1 | 2019 | 1711 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2017 | 40559 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2022 | 3486 | 0.020 |
Why?
|
| Diffusion | 1 | 2011 | 832 | 0.020 |
Why?
|
| Consensus | 2 | 2008 | 2960 | 0.020 |
Why?
|
| Affect | 1 | 2015 | 1475 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2014 | 9145 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15078 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2011 | 811 | 0.020 |
Why?
|
| United States | 5 | 2015 | 69872 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2013 | 2026 | 0.020 |
Why?
|
| Reaction Time | 1 | 2013 | 2098 | 0.020 |
Why?
|
| Receptors, GABA-A | 1 | 2010 | 627 | 0.020 |
Why?
|
| Genomics | 1 | 2022 | 5717 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 3252 | 0.020 |
Why?
|
| Age Factors | 2 | 2016 | 18373 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 2506 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 8319 | 0.020 |
Why?
|
| Oxygen | 1 | 2016 | 4189 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 1953 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 7785 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 3326 | 0.010 |
Why?
|
| Self Report | 1 | 2014 | 3553 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2018 | 77460 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 15535 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12802 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 1584 | 0.010 |
Why?
|
| Educational Status | 1 | 2008 | 2540 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14723 | 0.010 |
Why?
|
| Aging | 1 | 2018 | 8664 | 0.010 |
Why?
|
| Data Collection | 1 | 2008 | 3339 | 0.010 |
Why?
|
| Risk Factors | 2 | 2016 | 72296 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 41005 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2010 | 12025 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 5321 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2011 | 5101 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 4216 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 10400 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 13882 | 0.010 |
Why?
|